ChiCTR2000032585 版本V1.0 版本创建时间2020/05/03 14:45:00 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000032585 

最近更新日期:

Date of Last Refreshed on:

2020-05-03 14:44:56 

注册时间:

Date of Registration:

1990-01-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

中低位直肠癌预防性回肠造口术后还纳时间临床研究

Public title:

Clinical study on the retraction time after preventive ileostomy in middle and low rectal cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中低位直肠癌预防性回肠造口术后还纳时间临床研究

Scientific title:

Clinical study on the retraction time after preventive ileostomy in middle and low rectal cancer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

盛伟伟 

研究负责人:

周建平 

Applicant:

Sheng Weiwei 

Study leader:

Zhou Jianping 

申请注册联系人电话:

Applicant telephone:

13898805796

研究负责人电话:

Study leader's telephone:

13840509519

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

cmu_wwsheng@sina.com

研究负责人电子邮件:

Study leader's E-mail:

zjphama@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

沈阳市和平区南京北街155号

研究负责人通讯地址:

沈阳市和平区南京北街155号

Applicant address:

155 Nanjing North Street, HePing District, Shenyang

Study leader's address:

155 Nanjing North Street, HePing District, Shenyang

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国医科大学附属第一医院

Applicant's institution:

The First Hospital, China Medical University

研究负责人所在单位:

中国医科大学附属第一医院

Affiliation of the Leader:

The First Hospital, China Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

[2020]2019-315-3

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国医科大学附属第一医院医学科学研究伦理委员会

Name of the ethic committee:

Medical Science Research Ethics Committee of the First Affiliated Hospital of China Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-04-23 00:00:00

伦理委员会联系人:

王印博

Contact Name of the ethic committee:

Wang Yinbo

伦理委员会联系地址:

沈阳市和平区南京北街155号

Contact Address of the ethic committee:

155 Nanjing North Street, HePing District, Shenyang

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国医科大学附属第一医院

Primary sponsor:

The First Hospital, China Medical University

研究实施负责(组长)单位地址:

沈阳市和平区南京北街155号

Primary sponsor's address:

155 Nanjing North Street, HePing District, Shenyang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁

市(区县):

沈阳

Country:

China

Province:

Liaoning

City:

Shenyang

单位(医院):

中国医科大学附属第一医院

具体地址:

和平区南京北街155号

Institution
hospital:

The First Hospital, China Medical University

Address:

155 Nanjing Street North, Heping District

经费或物资来源:

Source(s) of funding:

none

Target disease:

rectal cancer

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

探讨行预防性回肠造口的中低位直肠癌患者造口还纳最佳时间。  

Objectives of Study:

To explore the best time for stoma recurrence in patients with middle and low rectal cancer who have a preventive ileostomy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.中低位直肠癌患者(CT示肿瘤位于腹膜反折以下;肠镜示肿瘤下缘距离齿状线10cm以内3cm以上)。
2.患者行保肛直肠癌根治术合并预防性造口的患者,围手术期间无吻合口瘘征象。
3.TNM分期为I-III期。
4.年龄大于18岁小于80岁。
5.第一手术距离二次造口还纳时间小于6月。
6.签署知情同意书

Inclusion criteria

1. Patients with middle and low rectal cancer (CT shows that the tumor is located below the peritoneal reflex; colonoscopy shows that the lower edge of the tumor is more than 3 cm within 10 cm of the dentate line).
2. Patients undergoing radical resection of rectal cancer with prophylactic stoma, no signs of anastomotic leakage during perioperative period.
3. TNM staging is I-III.
4. Age is between 18 years old.
5. The retraction time is less than six months from the last ostomy.
6. Sign the informed consent

排除标准:

1.IV期直肠癌患者;或无法行根治性切除。
2.高位直肠癌患者(CT示肿瘤位于腹膜返折以上,肠镜示肿瘤拒齿状线10cm以上)。
3.年龄大于80岁以上。
4.合并严重心肺功能异常无法耐受二次手术;或实施手术前发现肿瘤复发或转移。

Exclusion criteria:

1. Patients with stage IV rectal cancer; or no radical resection.
2. Patients with high rectal cancer (CT shows that the tumor is located above the peritoneal reflex, and the colonoscopy shows that the tumor is more than 10 cm above the dentate line)
3. Age is greater than 80 years old.
4. Patients with severe cardiopulmonary dysfunction can not tolerate secondary surgery or tumor recurrence or metastasis is found before surgery.

研究实施时间:

Study execute time:

From 2020-06-01 00:00:00 To 2025-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-06-01 00:00:00 To 2022-05-31 00:00:00  

干预措施:

Interventions:

组别:

15天组

样本量:

15

Group:

15 days group

Sample size:

干预措施:

预防性造口后15天行造口还纳术

干预措施代码:

A

Intervention:

Retraction will be performed at 15 days after prophylactic stoma

Intervention code:

组别:

3个月组

样本量:

15

Group:

3 months group

Sample size:

干预措施:

预防性造口后3个月行造口还纳术

干预措施代码:

B

Intervention:

Retraction will be performed at 3 months after prophylactic stoma

Intervention code:

组别:

6个月组

样本量:

15

Group:

3 months group

Sample size:

干预措施:

预防性造口后6个月行造口还纳术

干预措施代码:

C

Intervention:

Retraction will be performed at 6 months after prophylactic stoma

Intervention code:

组别:

术后辅助治疗15天还纳组

样本量:

15

Group:

15 days group(postoperative adjuvant treatment)

Sample size:

干预措施:

预防性造口后决定行术后辅助治疗同时术后15天行造口还纳术

干预措施代码:

a

Intervention:

Retraction will be performed at 15 days after prophylactic stoma to the patients requiring postoperative chemotherapy

Intervention code:

组别:

术后辅助治疗3个月还纳组

样本量:

15

Group:

3 months group (postoperative adjuvant treatment)

Sample size:

干预措施:

预防性造口后决定行术后辅助治疗同时术后3个月行造口还纳术

干预措施代码:

b

Intervention:

Retraction will be performed at 3 months after prophylactic stoma to the patients requiring postoperative chemotherapy

Intervention code:

组别:

术后辅助治疗6个月还纳组

样本量:

15

Group:

6 months group (postoperative adjuvant treatment)

Sample size:

干预措施:

预防性造口后决定行术后辅助治疗同时术后6个月行造口还纳术

干预措施代码:

c

Intervention:

Retraction will be performed at 6 months after prophylactic stoma to the patients requiring postoperative chemotherapy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁 

市(区县):

沈阳 

Country:

China 

Province:

Liaoning 

City:

Shenyang 

单位(医院):

中国医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Hospital, China Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

造口并发症

指标类型:

主要指标

Outcome:

Ostomy complications

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肛门功能锻炼评分

指标类型:

主要指标

Outcome:

Anal functional exercise score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

自我护理能力评分

指标类型:

次要指标

Outcome:

ESCA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

适应评分

指标类型:

次要指标

Outcome:

OAS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

领悟社会支持量表评分

指标类型:

次要指标

Outcome:

PSSS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量问卷

指标类型:

附加指标

Outcome:

Quality of life questionnaire

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

造口还纳率

指标类型:

主要指标

Outcome:

Ostomy retraction rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术早期并发症

指标类型:

主要指标

Outcome:

Early complications of surgery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术晚期并发症

指标类型:

主要指标

Outcome:

Late complications of surgery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

化疗时机选择

指标类型:

主要指标

Outcome:

Timing of chemotherapy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

医疗费用

指标类型:

主要指标

Outcome:

Medical expenses

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

按受试者术后是否需要辅助治疗分到化疗层和非化疗层,每层受试者被采用随机数表法随机分配到各组

Randomization Procedure (please state who generates the random number sequence and by what method):

According to whether the patients need adjuvant therapy after operation, they are divided into the chemotherapy layer and the non-chemotherapy layer. The subjects in each layer are randomly assigned to each group using the random number table method.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

采用此网络平台,在试验完成后6个月内公开;网络平台名称:中国临床试验注册中心;网址:www.chictr.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Use this network platform and make it public within 6 months after the completion of the test;Network platform name:Chinese clinical trial registry;URL:www.chictr.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-05-03 14:44:56